Clinical trials: Bladder
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
- Trial name
- NCT02365766
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Jason R. Brown
Recurrent Bladder Carcinoma, Stage II Bladder Cancer
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer.
- Conditions
- Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Trial name
- NCT01938573
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Urinary Bladder, Underactive
Amplifying Sensation in Underactive Bladder
The purpose of this study is to determine the influence of intravesical (bladder) electrical stimulation and intraurethral electrical stimulation on bothersome symptoms and bladder function in neurologically-intact adult women…
- Trial name
- AMPLIFY (NCT04516434)
- Testing
- Neurometer Neurotron CPT, Cystometry, Pressure-flow study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Obesity, Overactive Bladder
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only.
- Conditions
- Obesity, Overactive Bladder, Incontinence
- Trial name
- NCT00932022
- Testing
- Trospium Chloride, Extended Release (XR)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma, Refractory Bladder Carcinoma
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs…
- Conditions
- Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
- Trial name
- NCT04502095
- Testing
- Clindamycin, Diary, Ertapenem
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Roswell Park Cancer Institute
Infiltrating Bladder Urothelial Carcinoma
Bristol Bladder Trial
26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior…
- Trial name
- NCT01616875
- Testing
- Cabazitaxel + Cisplatin chemotherapy
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Urothelial Carcinoma
A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment…
- Trial name
- AVENANCE (NCT04822350)
- Testing
- Avelumab
- Where
- 81 sites in France
- Volunteers
- 596 people
- Sponsor
- Pfizer
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Nocturia
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients.
- Trial name
- NOC (NCT01184859)
- Testing
- Desmopressin
- Where
- 36 sites in Japan
- Volunteers
- 116 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Bladder Neoplasms
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder…
- Trial name
- NCT04430036
- Testing
- AGEN1884, AGEN2034, Cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Urge Urinary Incontinence, Overactive Bladder
Anticholinergic vs. Botox Comparison Study
Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary…
- Trial name
- ABC (NCT01166438)
- Testing
- Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg
- Where
- 11 sites in United States
- Volunteers
- 249 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Myeloproliferative Disorder, Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time.
- Conditions
- Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
- Trial name
- NCT00588666
- Testing
- Bevacizumab, Carboplatin, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Interstitial Cystitis, Painful Bladder Syndrome
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
- Trial name
- NCT00919113
- Testing
- 2% sodium chondroitin sulfate
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Watson Pharmaceuticals
Bladder Integrity, Bladder Function
Trendelenburg, Abdominal Insufflation and Time to Completion of Cystoscopy
Objective: The investigators seek to compare the efficiency of the cystoscopy with two interventions: 1. patient position during the cystoscopy (Trendelenburg (head down) or flat) 2.
- Conditions
- Bladder Integrity, Bladder Function, Ureteral Integrity, Ureteral Function
- Trial name
- NCT05786391
- Testing
- Flat position, Trendelenburg position, Insufflation
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer